Autoimmunity and anti-TNF-α agents

Annals of the New York Academy of Sciences

Volumn 1051, Issue , 2005, Pages 559-569

  Atzeni, Fabiola ^a   Turiel, Maurizio ^b   Capsoni, Franco ^c   Doria, Andrea ^d   Meroni, Pierluigi ^c   Sarzi Puttini, Piercarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adalimumab; Anticyclic citrullinated peptide antibodies (anti CCP); Autoantibodies; Autoimmunity; Etanercept; Infliximab; Rheumatoid factor

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DNA ANTIBODY; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PHOSPHOLIPID ANTIBODY; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ANKYLOSING SPONDYLITIS; ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BINDING AFFINITY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CROHN DISEASE; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LUPUS LIKE SYNDROME; LYMPHOMA; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; NEUTROPENIA; NONHUMAN; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ANAS;

EID: 25444502974     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1361.100     Document Type: Conference Paper

References (65)

1. SkaPENKO, A., J.R. KALDEN & H. SCHULZE-KOOPS. 2001. Treatment of rheumatoid arthritis in the third millennium. Scand. J. Rheumatol. 30: 249-254.
2. MCLAIN, D.A. 2001. Rheumatoid arthritis: update on new therapies. South Med. J. 94: 893-895.
3. CALABRESE, L.H. 2003. Molecular differences in anticytokine therapies. Clin. Exp. Rheumatol. 21: 241-248.
4. BENCSATH, M., A. BLASKOVITS & J. BORVENDEG. 2003. Biomolecular cytokine therapy. Pathol. Onc. Res. 9: 25-29.
5. SHARMA, P.K., D. HOTA & P. PANDHI. 2004. Biologies in rheumatoid arthritis. Japi 52: 231-236.
6. FELDMANN, M., P.M. BRENNAN & R.N. MAINI. 1996. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 14: 397-440.
7. VASSALLI, P. 1987. The pathophysiology of tumor necrosis factors. N. Engl. J. Med. 316: 379-385.
8. ELLIOTT, M.J., R.N. MAINI & M. FELDMANN. 1994. Randomized double-blind comparison of chimeric monoclonal antibody tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110.
9. FELSON, D.T., J.J. ANDERSON, M. BOERS, et al. 1993. The American College preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 36: 729-740.
10. KAVANAUGH, A., E.W. ST, CLAIR, W.J. MCCUNE, et al. 2000. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J. Rheumatol. 27: 841-850.
11. MAINI, R., E.W. ST. CLAIR, F. BREEDVELD, et al. 1999. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354: 1932-1939.
12. LIPSKY, P.E., D.M. VAN DE HEIJDE, E.W. ST. CLAIR, et al. 2000. 102-week clinical and radiological results from the ATTRACT trial: a 2 year, randomized, controlled, phase 3 trial of infliximab in patients with active RA despite MTX. Arthritis Rheum. 43: abstr. 269.
13. LIPSKY, P.E., D.M. VAN DER HEIJDE, E.W. ST. CLAIR, et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343: 1594-1602.
14. PRESENT, D.H., P. RUTGEERTS, S. TARGAN, et al. 1999. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340: 1398-1405.
15. BRANDT, J., H. HAIBEL, D. CORNELY, et al. 2000. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 43: 1346-1352.
16. BRAUN, J., J. BRANDT, J. LISTING, et al. 2002. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359: 1187-1193.
17. MORELAND, L.W., G. MARGOLIES, L.W. HECK, et al. 1996. Recombinant solubile tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J. Rheumatol. 23: 1849-1855.
18. MORELAND, L.W., S.B. COHEN, S.W. BAUMGARTNER, et al. 2001. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J. Rheumatol. 28: 1238-1244.
19. MORELAND, L.W., M.H. SCHIFF, S.W. BAUMGARTNER, et al. 1999. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Ann. Intern. Med. 130: 478-486.
20. MARTIN, R., E. RUDERMAN, R. FLEISCHMANN, et al. 2000. A phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis. Ann. Rheum. Dis. 59: 48.
21. GENOVESE, M.C., J.M. BATHON, R.W. MARTIN, et al. 2002. Etanercept vs methotrexate in patients with early rheumatoid arthritis: two-year radiography and clinical outcomes. Arthritis Rheum. 46: 1443-1450.
22. KIETZ, D.A., PH. PEPMUELLER & T.L. MOORE. 2001. Clinical response to etanercept in polyarticular course juvenil arthritis. J. Rheumatol. 28: 360-362.
23. MEASE, P.J., B.S. GOFFE, J. METZ, et al. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356: 385-390.
24. BRANDT, J., J. LISTING, J. SIEPER, et al. 2004. Development and presentation of criteria for short term improvement after TNF alpha treatment in ankylosing spondylitis. Ann. Rheum. Dis. 63: 1438-1444.
25. MEASE, P.J. 2003. Disease-modifying anthireumatic drugs therapy for spondyloarthropathies: advances in treatment. Curr. Opin. Rheumatol. 15: 12-25.
26. KEYSTONE, E. & B. HARAOUI. 2004. Adalimumab therapy in rheumatoid arthritis. Rheum. Dis. Clin. N. Am. 30: 349-364.
27. WEINBLATT, M.E., E.G. KEYSTONE, D.E. FURST, et al. 2003. Adalimumab, a fully human antitumor necrosis factor-monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum. 48: 35-39.
28. FURST, D.E., E. SCHIFF, R. FLEISCHMAN, et al. 2002. Safety and efficacy of adalimumab, a fully human anti-TNF-α monoclonal antibody, given in combination with stardard antirheumatic therapy: safety trial of adalimumab in rheumatoid arthritis (STAR). Arthritis Rheum. 46: S572.
29. VAN GESTEL, A.M., M.L. PREVOO, T. VAN HOFMA, et al. 1996. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with preliminary American College of Rheumatology and World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum. 39: 34-40.
30. BOMBARDIERI, S., A.G. TZIOUFAS, F. MCKENNA, et al. 2004. Efficacy evaluation of adalimumab (Humira) in patients with a single and multiple prior biologics in the ReAct Trial. Arthritis Rheum. 50 (suppl.9): abstr. 365.
31. DAY, R. 2002. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet 359: 540-541.
32. ANTONI, C. & J. BRAUN. 2002. Side effects of anti-TNF therapy: current knowledge. Clin. Exp. Rheumatol. 20: 152-157.
33. ZIOLKOWSKA, M. & W. MASLINSKI. 2003. Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis. Curr. Opin. Rheumatol. 15: 267-273.
34. MEYER, O., C. LABARRE, M. DOUGADOS, et al. 2003. Anticitrullinated peptide antibody assays in early rheumatoid arthritis for predicting five years radiographic damage. Ann. Rheum. Dis. 42: 677-680.
35. BOBBIO-PALLAVICINI, F., C. ALPINI, R. CAPORALI, et al. 2004. Autoantibody profile in rheumatoid arthritis during long-term inflimab treatment. Arthritis Res. Ther. 6: 264-272.
36. ALESSANDRI, C., M. BOMBARDIERI, N. DEL PAPA, et al. 2004. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following ant-TNF therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann. Rheum. Dis. 63: 1218-1221.
37. ATZENI, F., P. SARZI-PUTTINI, D. DELL'ACQUA, et al. 2005. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titre reduction and anti-nuclear antibody appearance: a one year prospective study. Submitted for publication.
38. REPARON-SCHIJT, C.C., W.J. VAN ESCH, C. VAN KOOTEN, et al. 1988. Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients. Arthritis Rheum. 41: 2211-2220.
39. BAERT, F., M. NOMAN, S. VERMEIRE, et al. 2003. Influence of immunogenicity on the long-term efficacy of Infliximab in Crohn's disease. N. Engl. J. Med. 348: 601-608.
40. HANAUER, S.B., B.G. FEAGAN, G.R. LICHTENSTEIN, et al. 2002. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541-1549.
41. MAINI, R.N., EC. BREEDVELD, J.R. KALDEN, et al. 1988. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41: 1552-1563.
42. CHARLES, P.J., R.J. SMEENK, J. DE JONG, et al. 2000. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 43: 2383-2390.
43. DE RYCKE, L., E. KRUITHOF, N. VAN DAMME, et al. 2003. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. 48: 1015-1023.
44. VERMEIRE, S., M. NOMAN, G. VAN ASSCHE, et al. 2003. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125: 32-39.
45. ANTIVALLE, M., G. RANDISI, M. MARRAZZA, et al. 2002. Clinical relevance of the induction of antibodies to double-stranded DNA during long-term treatment of rheumatoid arthritis with Infliximab. Ann. Rheum. Dis. Abstr. 0166.
46. ALLANORE, Y., J. SELLAM, F. BATTEUX, et al. 2004. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin. Exp. Rheum. 22: 756-758.
47. DE BANDT, M.J., V. DESCAMPS & O. MEYER. 2001. Two cases of etanercept-induced systemic lupus erythematosus in patients with rheumatoid arthritis. Ann. Rheum. Dis. 60: 175.
48. SHAKOOR, N., M. MICHALSKA, C.A. HARRIS, et al. 2002. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359: 579-580.
49. SARZI-PUTTINI, P., S. ARDIZZONE, G. MANZIONNA, et al. 2003. Infliximab-induced lupus in Crohn's disease: a case report. Dig. Liver Dis. 35: 814-817.
50. BOEHM, L.B., G.A. BOEHM & R. BAUER. 1998. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol. Int. 18: 59-62.
51. MILTENBURG, A.M.M., A. ROOS, L. SLEGTENHORST, et al. 1993. IgA anti-dsDNA antibodies in SLE: occurrence, incidence and association with clinical and laboratory variables of disease activity. J. Rheumatol. 20: 53-58.
52. AMOURA, Z., S. KOUTOUZOV & J.C. PIETTE. 2000. The role of nucleosomes in lupus. Curr. Opin. Rheumatol. 12: 369-373.
53. BERNSTEIN, R. 1996. Autoantibodies to histones, Sm and ubiquitins. In Manual of Biological Markers of Disease. W.J. Van Venrooij & R.N. Maini, Eds. C2.: 1-7. Kluwer Academic Publishers. Dordrecht, the Netherlands.
54. FERRERO-PEYRET, C., F. COURY, J.G. TEBIB, et al. 2004. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res. Ther. 6: 535-543.
55. LUGERING, A., M. SCHMIDT, N. LUGERING, et al. 2001. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121: 1145-1157.
56. BELL, D.A. & B. MORRISON. 1991. The spontaneous apoptotic cell death of normal human lymphocytes in vitro: the release of, and immunoproliferative response to, nucleosomes in vitro. Clin. Immunol. Immunopathol. 60: 13-26.
57. CAMPBELL, I.K., K. O'DONNELL, K.E. LAWLOR, et al. 2001. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J. Clin. Invest. 107: 1519-1527.
58. FIELDS, R.A., H. TOUBBEH, R.P. SEARLES, et al. 1989. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J. Rheumatol. 16: 623-625.
59. KEANE, A., R. WOODS, V. DOWDING, et al. 1987. Anticardiolipin antibodies in rheumatoid arthritis. Br. J. Rheumatol. 26: 346-350.
60. WOLF, P., J. GRETLER, F. AGLAS, et al. 1994. Anticardiolipin antibodies in rheumatoid arthritis: their relation to rheumatoid nodules and cutaneous vascular manifestations. Br. J. Dermatol. 131:48-51.
61. KAPIOTIS, S., W. SPEISER, I. PABINGER-FASCHING, et al. 1991. Anticardiolipin antibodies in patients with venous thrombosis. Haemostasis 21: 19-24.
62. ELLIOTT, M.J., R.N. MAINI, M. FELDMANN, et al. 1993. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum. 36: 1681-1690.
63. RANKIN, E.C., E.H. CHOY, D. KASSIMOS, et al. 1995. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 34: 334-342.
64. FERRACCIOLI, G., M. MECCHIA, E. DI POI, et al. 2002. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann. Rheum. Dis. 1:358-361.
65. JONSDOTTIR, T., J. FORSLID, M.A. VAN VOLLENHOVEN, et al. 2004. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann. Rheum. Dis. 63: 1075-1078.